Paridiprubart Biosimilar - Research Grade

Human

TLR4

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

O00206

7099

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-TLR4 antibody paridiprubart, supplied for research use only. It reproduces the target specificity of the originator molecule, binding human Toll-like receptor 4 (TLR4, UniProt O00206), and is intended as a laboratory reagent rather than a clinical drug. It is not for human or veterinary use. As a research-grade biosimilar it is well suited to functional and mechanistic studies: as a positive or benchmarking control alongside other TLR4-directed reagents, for in-vitro receptor-binding and neutralisation assays, for probing TLR4-dependent signalling in cell-based systems, and as a starting reagent for ADCC or antibody-drug-conjugate development workflows. The human IgG1/kappa framework supports Fc-mediated assay formats and epitope-competition studies. Material is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities, making it appropriate for reproducible in-vitro work and preclinical model characterisation where consistent, well-defined anti-TLR4 reagent is required. Toll-like receptor 4 (TLR4) is a type I transmembrane pattern-recognition receptor and a central sensor of innate immunity. Its best-characterised ligand is lipopolysaccharide (LPS) from Gram-negative bacteria, which it recognises together with the accessory proteins MD-2 (LY96), CD14 and LBP. Ligand-induced dimerisation of the TLR4/MD-2 complex triggers intracellular signalling through the TIR-domain adaptors MyD88 and TRIF, activating NF-kB and IRF3 pathways and driving production of pro-inflammatory cytokines and type I interferons. Beyond LPS, TLR4 responds to endogenous damage-associated molecular patterns (DAMPs) such as HMGB1, S100 proteins and heat-shock proteins, linking it to sterile inflammation and tissue injury. Because of this role, TLR4 is studied extensively in sepsis, acute lung injury, ischemia-reperfusion, autoimmunity and inflammatory disease, and is a recognised therapeutic target for modulating excessive innate immune activation.

hToll, Toll-like receptor 4

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Paridiprubart (anti-TLR4) Biosimilar

Q: Is the Paridiprubart biosimilar available in bulk or gram quantities?

A: Yes — the Paridiprubart biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Paridiprubart suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Paridiprubart biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Paridiprubart that binds TLR4; for research use only (RUO).